United States Patent 7,056,890: Scope, Claims, Expiration, and Patent Landscape for Phentermine-Topiramate

U.S. Patent No. 7,056,890 covered combinations of phentermine and topiramate, their administration for weight loss, controlled-release formulations, dose-escalation regimens, and kits. The patent issued on June 6, 2006, and its 20-year term from the earliest claimed priority date ended on December 3, 2022. The patent is therefore expired and cannot currently block generic manufacture, sale, or use in the United States. [1][2]

The claims were broad in subject matter but varied substantially in practical commercial relevance. The strongest historical coverage targeted a pharmaceutical dosage form combining immediate-release phentermine with controlled-release topiramate, including a core-and-coating structure. Method claims separately covered administration of the two drugs, dose titration, once-daily use, and treatment of obesity-related conditions.

What does U.S. Patent 7,056,890 cover?

The patent covers four principal technology groups:

Claim group	Claims	Subject matter
Pharmaceutical compositions	1-7	Phentermine-topiramate combinations and release profiles
Weight-loss methods	8-45	Dosing, administration routes, timing, titration, and formulation
Obesity-related treatment	46-48	Treatment of side effects associated with obesity
Kits	49-54	Separate dosage forms or combined controlled-release dosage forms

The patent does not require a specific salt, excipient, capsule, tablet, patient body-mass index, or named commercial product unless those limitations appear in a particular dependent claim.

At the independent-claim level, claim 1 covers a composition containing:

About 50 mg to 250 mg of topiramate; and
About 5 mg to 15 mg of phentermine.

Claim 8 covers a method using the same daily dose ranges. Claim 38 adds a titration sequence in which topiramate begins at a lower dose and increases to a maintenance dose. Claim 49 covers a kit with separate phentermine and topiramate dosage forms. Claim 52 covers a sealed package containing controlled-release dosage forms that provide immediate phentermine release and delayed topiramate release.

How broad are the composition claims?

Claim 1 is a composition claim defined primarily by active-ingredient amounts. It does not require:

Controlled release;
Immediate release;
Oral administration;
A particular ratio of the two ingredients;
A specific formulation architecture; or
A diagnosis of obesity.

A product containing 100 mg of topiramate and 10 mg of phentermine would fall within the literal numerical ranges of claim 1, subject to the legal meaning of “about” and the claim’s other limitations.

Claims 2 and 3 narrow the topiramate range:

Claim	Topiramate range	Phentermine range
1	About 50-250 mg	About 5-15 mg
2	About 100-250 mg	About 5-15 mg
3	About 100-200 mg	About 5-15 mg

The nested structure gives the patent holder multiple claim positions. If the broad 50-250 mg range were challenged, the 100-250 mg and 100-200 mg ranges could provide narrower fallback positions. The claims do not establish a fixed phentermine-to-topiramate ratio.

What formulations are protected by U.S. Patent 7,056,890?

Claims 4-7 target release characteristics. Claim 4 requires:

Immediate release of phentermine; and
Controlled release of topiramate.

Claim 5 narrows the dosage form to a core containing topiramate and a coating containing phentermine. Claim 6 requires delayed release of topiramate, while claim 7 requires both delayed and sustained release.

The formulation claims can be represented as follows:

Claim	Formulation limitation
4	Immediate-release phentermine and controlled-release topiramate
5	Topiramate core and phentermine coating
6	Delayed release of topiramate
7	Delayed and sustained release of topiramate
30	Same release relationship in a method claim
31	Oral core-and-coating dosage form
32-34	Delayed and/or sustained topiramate release
35	Granules, hydrogels, matrices, or combinations
37	Barrier between core and coating

The formulation claims are materially narrower than claim 1. A product containing the two active ingredients in a conventional immediate-release tablet could satisfy claim 1 if the dose ranges are met, but it would not necessarily satisfy claim 4, which requires a particular release relationship.

The phrase “controlled release” would be construed in the context of the specification and prosecution history. It generally requires release behavior that differs from ordinary immediate release. The specification’s references to delayed, sustained, matrix, hydrogel, and granule systems provide technical context, but claim scope would depend on the precise construction adopted in litigation.

How do the claims compare with Qsymia?

Qsymia is an extended-release combination of phentermine hydrochloride and topiramate. The FDA-approved strengths are:

Qsymia strength	Phentermine	Topiramate
Initial dose	3.75 mg	23 mg
Recommended dose	7.5 mg	46 mg
Escalation dose	11.25 mg	69 mg
Maximum dose	15 mg	92 mg

[3]

The relationship between Qsymia and the claims of Patent 7,056,890 is mixed.

The initial 3.75 mg/23 mg and 7.5 mg/46 mg strengths fall below claim 1’s stated minimums of 5 mg phentermine and 50 mg topiramate. The 11.25 mg/69 mg and 15 mg/92 mg strengths fall within claim 1’s numerical ranges. The maximum 15 mg/92 mg strength also falls within claims requiring about 15 mg phentermine and at least about 50 mg topiramate.

Qsymia’s extended-release design is commercially relevant to claims 4-7 and 30-37 because those claims require immediate phentermine release with controlled, delayed, or sustained topiramate release. The exact infringement analysis would depend on the approved product’s release profile, formulation structure, and claim construction.

Claim 36 requires 5-15 mg of phentermine and 100-200 mg of topiramate. The marketed Qsymia strengths top out at 92 mg of topiramate, so the approved maximum strength does not literally satisfy the 100-200 mg limitation in claim 36.

What method-of-use claims does the patent contain?

Claims 8-48 cover methods rather than compositions. Their scope includes several distinct concepts.

Dose ranges and patient populations

Claims 8-12 cover daily administration of:

50-250 mg topiramate; and
5-15 mg phentermine.

Claims 11 and 12 limit the subject to an overweight or obese person. Claim 13 expressly covers a subject who is neither overweight nor obese. That claim broadens the method beyond conventional obesity treatment, although it still requires administration for effecting weight loss.

Claims 46-48 focus on treatment of at least one side effect associated with obesity. These claims require an obese subject and the same general topiramate and phentermine dose ranges.

Separate or simultaneous administration

Claims 14-16 cover separate administration, including administration at different times of day. Claim 16 specifies morning phentermine and topiramate later in the day.

Claims 23-29 cover oral, transdermal, injection, simultaneous, single-formulation, unit-dose, and once-daily administration. The inclusion of transdermal and injectable administration expands the literal method language beyond the principal commercial oral product.

Release profiles

Claims 17-21 distinguish immediate-release phentermine from immediate-release, delayed-release, or sustained-release topiramate. Claims 30-37 apply similar limitations when the two ingredients are contained in one formulation.

Claim 35 identifies specific controlled-release technologies:

Granules;
Hydrogels;
Matrix formulations; and
Combinations of those systems.

Claim 37 adds a barrier between the core and coating to limit topiramate release. This limitation is directed to a multi-layer or coated dosage form rather than a simple blend.

What dose-escalation regimen is protected?

Claims 38-45 cover gradual topiramate escalation from an initial dose to a maintenance dose, while phentermine is administered at 5-15 mg daily.

Claim 39 specifies an initial topiramate dose of about 25 mg. Claim 44 requires increases on an approximately weekly basis. Claim 45 describes a detailed titration schedule:

Period	Topiramate dose
First 5-7 days	25 mg daily
Next 5-7 days	50 mg daily
Next 6-8 days	100 mg daily
Next 20-26 days	About 100-150 mg daily
Maintenance	100-200 mg daily

This regimen is commercially important because gradual topiramate escalation is consistent with the FDA-approved Qsymia titration approach, although the exact commercial dosing schedule and claim language must be compared element by element. A generic applicant could avoid literal infringement by using a materially different titration schedule, but that strategy would not eliminate potential exposure under the broader method claims if all limitations were still met.

What is the patent’s legal status and expiration date?

Event	Date
Earliest claimed priority	December 3, 2001
Patent issued	June 6, 2006
Expected 20-year expiration	December 3, 2022
Current status	Expired

[1][2]

The patent’s term was governed by the earliest effective U.S. nonprovisional or international filing date to which priority was properly claimed, rather than the issue date. The patent therefore did not receive a full 20 years from issuance.

Because Patent 7,056,890 expired in 2022, its claims no longer create an enforceable U.S. patent barrier. Historical infringement claims may be subject to separate limitation periods, but the patent cannot support a new prospective injunction against an otherwise lawful generic launch.

What was the FDA and Orange Book status?

Qsymia was approved by the FDA on July 17, 2012, under NDA 022580 for chronic weight management in specified adult patients with obesity or overweight status and weight-related comorbidities. [3]

The FDA Orange Book historically listed patents associated with Qsymia, including Patent 7,056,890 and later patents directed to commercial formulation and related technology. Orange Book listing is relevant to ANDA litigation while a patent remains unexpired. After expiration, the patent no longer provides a live patent-term block to approval or launch.

The FDA approval itself is separate from patent rights. FDA approval, pediatric exclusivity, clinical data exclusivity, and patent term operate under different statutes. Qsymia did not create a biosimilar pathway because it is a small-molecule drug, not a biologic. Generic applicants would use the ANDA pathway, typically with Paragraph IV certifications against unexpired listed patents.

Which patents later protected Qsymia?

The commercial Qsymia patent estate extended beyond Patent 7,056,890. Later patents were directed more specifically to formulation, release, dosage, and commercial product configurations. Public Orange Book and FDA labeling records identify additional Qsymia-related patents, including U.S. Patent Nos. 8,486,453 and 8,895,557. [3][4]

The strategic distinction is important:

Patent category	Primary risk
U.S. 7,056,890	Broad combination, method, titration, and kit claims; expired
Later formulation patents	Product-specific release and dosage-form challenges
Method-of-use patents	Label-induced infringement and carve-out issues
Manufacturing patents	Process access and supply-chain constraints

The later patents, rather than Patent 7,056,890 alone, determined the practical timing of generic Qsymia competition after December 2022.

Which companies challenged Qsymia patents?

Generic applicants seeking approval for phentermine/topiramate products could challenge Orange Book-listed patents through Paragraph IV certifications. Public litigation records and FDA patent listings should be reviewed patent by patent because an ANDA challenge to one Qsymia patent does not necessarily resolve other listed patents.

The typical defendants in this category have included major generic manufacturers and ANDA applicants seeking approval for equivalent extended-release combinations. Litigation exposure depends on:

The exact ANDA formulation;
The proposed label;
The Paragraph IV notice;
The asserted patent claims;
The filing date of the infringement action; and
Any settlement or licensing agreement.

Patent 7,056,890 itself is no longer a prospective litigation barrier because its term has expired. Current generic-entry risk instead turns on unexpired later patents, regulatory review, product-specific formulation differences, and commercial manufacturing capability.

How strong was the patent estate?

Historically, Patent 7,056,890 had meaningful breadth because it combined:

Ingredient ranges;
Release architecture;
Administration timing;
Dose escalation;
Patient populations;
Multiple administration routes; and
Separate and combined kits.

Its weaknesses were equally apparent. Several claims used broad functional language, including “controlled release,” “therapeutically effective,” “about,” and “extended time period.” The patent also included unusually broad route and population language that could create enablement, written-description, indefiniteness, or obviousness challenges depending on the asserted claim and prior art.

The strongest commercial claims were likely those tied to a concrete dosage form and a defined release relationship. The broadest numerical composition and method claims offered wider coverage but presented greater validity and claim-construction exposure.

What generic launch scenarios existed after expiration?

After December 3, 2022, three principal generic-launch scenarios became available:

Scenario	Description
Direct launch after 7,056,890 expiration	Available if no other unexpired patent blocked the product
Paragraph IV launch against later patents	Applicant challenges listed formulation or method patents
At-risk launch	Applicant launches before all patent disputes are finally resolved

A generic product matching only the low-dose Qsymia strengths could avoid some numerical limitations of Patent 7,056,890. A product matching the 11.25 mg/69 mg or 15 mg/92 mg strengths would have fit several expired claims, but expiration removed that barrier. Later formulation patents remained the principal patent consideration.

What licensing and commercial issues affect the estate?

Patent ownership, FDA sponsorship, commercialization, and manufacturing rights are separate questions. The key commercial asset was Qsymia, marketed under NDA 022580. Revenue exposure was tied to the product’s chronic-use obesity indication and the availability of competing generic or alternative anti-obesity medicines.

The relevant competitive set includes:

GLP-1 receptor agonists such as semaglutide and liraglutide;
Tirzepatide products;
Naltrexone/bupropion;
Orlistat; and
Generic phentermine monotherapy.

Qsymia’s patent value declined sharply after the expiration of Patent 7,056,890 because the patent covered the central pharmacologic combination and major administration concepts. Product-specific later patents and formulation know-how retained greater commercial importance.

Key Takeaways

U.S. Patent 7,056,890 covered phentermine-topiramate compositions, methods, titration regimens, release systems, and kits.
The broadest composition claim required about 50-250 mg topiramate and 5-15 mg phentermine.
Claims 4-7 and 30-37 focused on immediate-release phentermine with controlled, delayed, or sustained-release topiramate.
Claims 38-45 covered gradual topiramate escalation to a maintenance dose.
The upper Qsymia strengths, including 11.25 mg/69 mg and 15 mg/92 mg, fell within important numerical ranges of the expired patent.
The patent expired on December 3, 2022.
It no longer creates a prospective U.S. patent barrier to generic entry.
Qsymia’s later formulation and product patents were more relevant to post-2022 generic litigation.
No biosimilar pathway applies because phentermine and topiramate are small-molecule active ingredients.
Patent strength was highest for concrete release-profile and dosage-form claims and lower for broad functional and numerical claims.

FAQs About U.S. Patent 7,056,890

Did Patent 7,056,890 cover Qsymia?

Yes, several claims were broad enough to encompass higher-strength Qsymia combinations and release configurations, subject to claim construction and the specific product characteristics. The patent expired on December 3, 2022.

Can a generic manufacturer still infringe U.S. Patent 7,056,890?

The expired patent cannot support a new prospective infringement claim based on conduct occurring after expiration. Historical conduct before expiration raises separate limitation and litigation questions.

Did the patent cover phentermine alone?

No. The claims require phentermine together with topiramate. Phentermine monotherapy is outside the claimed combination requirements.

Did the patent require oral administration?

Not in all claims. Some method claims expressly covered oral administration, while others included transdermal, injectable, separate, simultaneous, and single-formulation administration.

What was the most commercially important claim concept?

The most commercially relevant concept was a single dosage form providing immediate release of phentermine and controlled, delayed, or sustained release of topiramate, particularly in an oral core-and-coating structure.

References

United States Patent and Trademark Office. (2006). U.S. Patent No. 7,056,890, Compositions and methods for treating obesity.
United States Patent and Trademark Office. (n.d.). Patent Center: U.S. Patent No. 7,056,890.
U.S. Food and Drug Administration. (2012). Qsymia prescribing information, NDA 022580.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	369126	⤷ Start Trial
Australia	2008262566	⤷ Start Trial
Australia	5489600	⤷ Start Trial
Australia	770068	⤷ Start Trial
Canada	2377330	⤷ Start Trial
Canada	2686633	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,056,890

Summary for Patent: 7,056,890